Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, March 21, 2016

Online patient research for MS patients NOT on MS Meds

The Find A Cure Panel has some confidential and anonymous online research for patients who have MS who are NOT CURRENTLY on a disease modifying MS treatment.

No personal identifying information is collected. 

All the researcher will see is a 16 digit respondent I.D. that looks like this: 

To qualify for this research, you must:
1)    Live in the US
2)    Have been diagnosed with MS
3)    NOT currently be on a disease modifying MS treatment.
4)    If you were previously on MS treatment but discontinued it or had never been on MS treatment then you qualify.
5)    If you are newly diagnosed but have not yet received your prescription, then you will NOT qualify. This research is focused on discontinued treaters and never been treated patients and not newly diagnosed patients.

PLEASE CLICK the LINK showing below to complete this important survey

If you complete the survey, FACP will donate $100 to MSVN.

To participate, please click on this survey link: 

If you have questions or issues with participating, then please email FACP at



No comments: